JP4803933B2 - インビトロ翻訳タンパク質の符号化方法および選別方法 - Google Patents

インビトロ翻訳タンパク質の符号化方法および選別方法 Download PDF

Info

Publication number
JP4803933B2
JP4803933B2 JP2001520897A JP2001520897A JP4803933B2 JP 4803933 B2 JP4803933 B2 JP 4803933B2 JP 2001520897 A JP2001520897 A JP 2001520897A JP 2001520897 A JP2001520897 A JP 2001520897A JP 4803933 B2 JP4803933 B2 JP 4803933B2
Authority
JP
Japan
Prior art keywords
protein
nucleic acid
rna
encoding
vitro translated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP2001520897A
Other languages
English (en)
Japanese (ja)
Other versions
JP2003508761A5 (https=
JP2003508761A (ja
Inventor
ロバート ジー． クイメリス
Original Assignee
ブリストル−マイヤーズ スクウィブ カンパニー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ブリストル−マイヤーズ スクウィブ カンパニー filed Critical ブリストル−マイヤーズ スクウィブ カンパニー
Publication of JP2003508761A publication Critical patent/JP2003508761A/ja
Publication of JP2003508761A5 publication Critical patent/JP2003508761A5/ja
Application granted granted Critical
Publication of JP4803933B2 publication Critical patent/JP4803933B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1062—Isolating an individual clone by screening libraries mRNA-Display, e.g. polypeptide and encoding template are connected covalently
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/04—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length on carriers
    • C07K1/047—Simultaneous synthesis of different peptide species; Peptide libraries
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
    • C07K1/1077—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of residues other than amino acids or peptide residues, e.g. sugars, polyols, fatty acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/13—Labelling of peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
JP2001520897A 1999-08-27 2000-08-25 インビトロ翻訳タンパク質の符号化方法および選別方法 Expired - Lifetime JP4803933B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US15126199P 1999-08-27 1999-08-27
US60/151,261 1999-08-27
PCT/US2000/023414 WO2001016352A1 (en) 1999-08-27 2000-08-25 Methods for encoding and sorting in vitro translated proteins

Publications (3)

Publication Number Publication Date
JP2003508761A JP2003508761A (ja) 2003-03-04
JP2003508761A5 JP2003508761A5 (https=) 2010-06-24
JP4803933B2 true JP4803933B2 (ja) 2011-10-26

Family

ID=22537976

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2001520897A Expired - Lifetime JP4803933B2 (ja) 1999-08-27 2000-08-25 インビトロ翻訳タンパク質の符号化方法および選別方法

Country Status (6)

Country Link
US (2) US6436665B1 (https=)
EP (1) EP1212452B1 (https=)
JP (1) JP4803933B2 (https=)
AU (1) AU779653B2 (https=)
CA (1) CA2382545C (https=)
WO (1) WO2001016352A1 (https=)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2323638A1 (en) * 1998-04-03 1999-10-14 Phylos, Inc. Addressable protein arrays
DE19923966C2 (de) * 1999-05-25 2003-04-24 Phylos Inc Erkennungssystem zur Auftrennung von Probenbestandteilen, seine Herstellung und Verwendung
DK1196637T3 (da) * 1999-07-27 2007-07-30 Adnexus Therapeutics Inc Peptidacceptor-ligeringsmetoder
US6436665B1 (en) * 1999-08-27 2002-08-20 Phylos, Inc Methods for encoding and sorting in vitro translated proteins
DE19959857C1 (de) * 1999-12-10 2001-06-28 Aventis Res & Tech Gmbh & Co Testsystem zum Nachweis von Analyten sowie ein Verfahren zur Herstellung und Verwendung
EP1423400B2 (en) 2001-03-19 2013-05-22 President and Fellows of Harvard College Evolving new molecular function
US20030027194A1 (en) * 2001-07-31 2003-02-06 Markus Kurz Modular assembly of nucleic acid-protein fusion multimers
AU2002365404A1 (en) * 2001-11-27 2003-06-10 Compound Therapeutics, Inc. Solid-phase immobilization of proteins and peptides
WO2004016767A2 (en) 2002-08-19 2004-02-26 The President And Fellows Of Harvard College Evolving new molecular function
US20050069896A1 (en) * 2002-09-12 2005-03-31 Horvitz H. Robert Rb pathway and chromatin remodeling genes that antagonize let-60 Ras signaling
WO2005017109A2 (en) * 2003-06-30 2005-02-24 Massachusetts Institute Of Technology Nucleic acids and polypeptides required for cell survival in the absence of rb
WO2005074417A2 (en) * 2003-09-03 2005-08-18 Salk Institute For Biological Studies Multiple antigen detection assays and reagents
KR101337320B1 (ko) * 2003-11-20 2013-12-06 사노피 파스퇴르 인크 백일해 독소의 정제방법 및 이에 유용한 펩타이드
WO2005086679A2 (en) 2004-03-05 2005-09-22 Medical College Of Ohio Methods and compositions for assessing nucleic acids and alleles
WO2005106036A2 (en) 2004-04-12 2005-11-10 Medical College Of Ohio Methods and compositions for assaying analytes
US20050260652A1 (en) * 2004-04-15 2005-11-24 The General Hospital Corporation Compositions and methods that modulate RNA interference
US7635563B2 (en) * 2004-06-30 2009-12-22 Massachusetts Institute Of Technology High throughput methods relating to microRNA expression analysis
DK2339014T3 (en) 2005-11-16 2015-07-20 Ambrx Inc Methods and compositions comprising non-natural amino acids
US7749957B2 (en) 2006-04-06 2010-07-06 E.I. Du Pont De Nemours And Company Clay-binding peptides and methods of use
US7951559B2 (en) * 2007-07-25 2011-05-31 E.I. Du Pont De Nemours And Company Recombinant peptide production using a cross-linkable solubility tag
US7829311B2 (en) 2007-07-25 2010-11-09 E.I. Du Pont De Nemours And Company Ketosteroid isomerase inclusion body tag engineered to be acid-resistant by replacing aspartates with glutamate
US7678883B2 (en) * 2007-07-25 2010-03-16 E.I. Du Pont De Nemours And Company Solubility tags for the expression and purification of bioactive peptides
US7794963B2 (en) 2007-11-02 2010-09-14 E.I. Du Pont De Nemours And Company Use of tetracysteine tags in fluorescence-activated cell sorting analysis of prokaryotic cells producing peptides or proteins
US8420081B2 (en) 2007-11-30 2013-04-16 Abbvie, Inc. Antibody formulations and methods of making same
US8883146B2 (en) 2007-11-30 2014-11-11 Abbvie Inc. Protein formulations and methods of making same
ES2836128T3 (es) 2008-04-16 2021-06-24 Univ Johns Hopkins Método para determinar variantes del receptor de andrógenos en cáncer de próstata
EP2316030B1 (en) 2008-07-25 2019-08-21 Wagner, Richard W. Protein screeing methods
US20100158846A1 (en) * 2008-12-18 2010-06-24 E. I. Du Pont De Nemours And Company Hair-binding peptides
US8287845B2 (en) * 2008-12-18 2012-10-16 E I Du Pont De Nemours And Company Hair-binding peptides
US20100158837A1 (en) 2008-12-18 2010-06-24 E. I. Du Pont De Nemours And Company Iron oxide-binding peptides
US20100158822A1 (en) * 2008-12-18 2010-06-24 E .I. Du Pont De Nemours And Company Peptides that bind to silica-coated particles
ES2638324T3 (es) 2009-02-13 2017-10-19 X-Chem, Inc. Métodos de creación y examen de bibliotecas codificadas por ADN
JP2012522057A (ja) * 2009-03-30 2012-09-20 ジヨンソン・アンド・ジヨンソン・コンシユーマー・カンパニーズ・インコーポレーテツド 化粧用剤の送達のためのペプチドに基づく系
US8481678B2 (en) 2009-03-30 2013-07-09 E I Du Pont De Nemours And Company Peptide-based tooth whitening reagents
WO2010138709A1 (en) 2009-05-28 2010-12-02 Government Of The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Anti-tnf induced apoptosis (atia) diagnostic markers and therapies
US20120296403A1 (en) 2010-02-10 2012-11-22 Novartis Ag Methods and compounds for muscle growth
SG191153A1 (en) 2010-12-23 2013-07-31 Hoffmann La Roche Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery
DE102010056289A1 (de) 2010-12-24 2012-06-28 Geneart Ag Verfahren zur Herstellung von Leseraster-korrekten Fragment-Bibliotheken
GB2502238A (en) 2011-02-15 2013-11-20 Univ Johns Hopkins Compositions and methods for diagnosing ovarian cancer
ES2926988T3 (es) 2011-03-15 2022-10-31 X Body Inc Métodos de cribado de anticuerpos
CN103732738A (zh) 2011-04-28 2014-04-16 小利兰斯坦福大学托管委员会 与样品相关的多核苷酸的鉴定
IN2014CN02574A (https=) 2011-09-07 2015-06-26 Chem Inc X
AU2012347972B2 (en) 2011-12-05 2018-05-10 X-Body, Inc. PDGF receptor beta binding polypeptides
SG10201907347YA (en) 2012-07-13 2019-09-27 X Chem Inc Dna-encoded libraries having encoding oligonucleotide linkages not readable by polymerases
EP2948775B1 (en) 2013-01-23 2018-10-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Compositions and methods for detecting neoplasia
RU2015137617A (ru) 2013-03-14 2017-04-18 Юниверсити Оф Мэриленд, Балтимор Офис Оф Текнолоджи Трансфер Агенты, подавляющие андрогенные рецепторы, и их применение
US20140327460A1 (en) * 2013-05-03 2014-11-06 Second Sight Medical Products, Inc. Test Apparatus and Method for Determining Long Term Reliability of an Implantable Device
CA3210220A1 (en) 2013-05-10 2014-11-13 Johns Hopkins University Compositions for ovarian cancer assessment having improved specificity
MY191368A (en) 2013-06-28 2022-06-20 X Body Inc Target antigen discovery, phenotypic screens and use thereof for identification of target cell specific target epitopes
EP3779440A1 (en) 2013-09-23 2021-02-17 X-Body, Inc. Methods and compositions for generation of binding agents against cell surface antigens
WO2015179404A1 (en) 2014-05-19 2015-11-26 The Johns Hopkins University Methods for identifying androgen receptor splice variants in subjects having castration resistant prostate cancer
CA2959336A1 (en) 2014-08-25 2016-03-03 The Johns Hopkins University Methods and compositions related to prostate cancer therapeutics
JP6478392B2 (ja) * 2014-12-26 2019-03-06 国立研究開発法人産業技術総合研究所 核酸リンカー
US11998540B2 (en) 2015-12-11 2024-06-04 The General Hospital Corporation Compositions and methods for treating drug-tolerant glioblastoma
US12130290B2 (en) 2016-11-29 2024-10-29 Trustees Of Tufts College Compositions and methods for diagnosing breast cancer
EP3669004A1 (en) 2017-08-16 2020-06-24 Medimmune, LLC Compositions and methods for treatment of atopic dermatitis and treatment selection
US11988663B2 (en) 2018-12-18 2024-05-21 The University Of Memphis Research Foundation Compositions and methods for the detection and molecular profiling of membrane bound vesicles
WO2022197933A1 (en) 2021-03-18 2022-09-22 The Broad Institute, Inc. Compositions and methods for characterizing lymphoma and related conditions
WO2023122723A1 (en) 2021-12-23 2023-06-29 The Broad Institute, Inc. Panels and methods for diagnosing and treating lung cancer
WO2025106804A1 (en) 2023-11-16 2025-05-22 Massachusetts Institute Of Technology Compositions and methods for characterizing hepatocyte stress
WO2025217069A1 (en) 2024-04-08 2025-10-16 Beth Israel Deaconess Medical Center, Inc. Compositions and methods for treating cardiotoxicity

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5639603A (en) * 1991-09-18 1997-06-17 Affymax Technologies N.V. Synthesizing and screening molecular diversity
JP2547149B2 (ja) * 1992-03-05 1996-10-23 三洋化成工業株式会社 免疫測定法及び免疫測定用試薬キット
GB2284208A (en) * 1993-11-25 1995-05-31 Pna Diagnostics As Nucleic acid analogues with a chelating functionality for metal ions
US5695934A (en) 1994-10-13 1997-12-09 Lynx Therapeutics, Inc. Massively parallel sequencing of sorted polynucleotides
ATE332368T1 (de) 1997-01-21 2006-07-15 Gen Hospital Corp Selektion von proteinen mittels rns-protein fusionen
US6261804B1 (en) 1997-01-21 2001-07-17 The General Hospital Corporation Selection of proteins using RNA-protein fusions
JPH10253632A (ja) * 1997-03-10 1998-09-25 Nissui Pharm Co Ltd 分析方法、キット及び装置
CA2323638A1 (en) * 1998-04-03 1999-10-14 Phylos, Inc. Addressable protein arrays
US6143503A (en) * 1998-04-17 2000-11-07 Whitehead Institute For Biomedical Research Use of a ribozyme to join nucleic acids and peptides
US5965352A (en) 1998-05-08 1999-10-12 Rosetta Inpharmatics, Inc. Methods for identifying pathways of drug action
JP4278872B2 (ja) * 1998-08-17 2009-06-17 フィロス インク． 蛋白質・核酸融合分子ライブラリーを用いた化合物・蛋白質相互作用の同定
US6436665B1 (en) * 1999-08-27 2002-08-20 Phylos, Inc Methods for encoding and sorting in vitro translated proteins

Also Published As

Publication number Publication date
US6436665B1 (en) 2002-08-20
CA2382545A1 (en) 2001-03-08
US20030013160A1 (en) 2003-01-16
WO2001016352A1 (en) 2001-03-08
AU6938700A (en) 2001-03-26
CA2382545C (en) 2013-08-13
EP1212452A4 (en) 2003-09-24
JP2003508761A (ja) 2003-03-04
EP1212452B1 (en) 2013-07-17
US7892785B2 (en) 2011-02-22
AU779653B2 (en) 2005-02-03
EP1212452A1 (en) 2002-06-12

Similar Documents

Publication Publication Date Title
JP4803933B2 (ja) インビトロ翻訳タンパク質の符号化方法および選別方法
JP2003508761A5 (https=)
US20220260581A1 (en) Peptide constructs and assay systems
EP1068356B1 (en) Addressable protein arrays
US7125669B2 (en) Solid-phase immobilization of proteins and peptides
US6258558B1 (en) Method for selection of proteins using RNA-protein fusions
JP4318721B2 (ja) ｍＲＮＡ−ピューロマイシン−タンパク質連結体作製用リンカー
US6261804B1 (en) Selection of proteins using RNA-protein fusions
JP2002522057A (ja) 蛋白質・核酸融合分子ライブラリーを用いた化合物・蛋白質相互作用の同定
US20240210410A1 (en) Determination of protein information by recoding amino acid polymers into dna polymers
JP5733784B2 (ja) ｃＤＮＡ／ｍＲＮＡ−タンパク質連結体の効率的合成法
WO2019148001A1 (en) Methods and composition for high throughput single molecule protein detection systems
WO2003062417A1 (fr) Produit de ligation arn-adn, et utilisation correspondante
JPWO2003048363A1 (ja) 対応付け分子とｃ末端ラベル化蛋白質の複合体および対応付け分子の複合体、ならびにそれらの複合体を利用した蛋白質間相互作用解析方法
WO2005001086A1 (ja) 固定化mRNA－ピューロマイシン連結体及びその用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20020319

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20050419

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20070824

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20090609

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20091109

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100205

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100215

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20100506

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100510

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100830

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20101129

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20101206

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110225

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110330

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110628

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20110803

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20110809

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

Ref document number: 4803933

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20140819

Year of fee payment: 3

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20100506

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

EXPY Cancellation because of completion of term